PMID- 24785939 OWN - NLM STAT- MEDLINE DCOM- 20150330 LR - 20191210 IS - 1399-0039 (Electronic) IS - 0001-2815 (Linking) VI - 84 IP - 2 DP - 2014 Aug TI - Evaluation of a competitive enzyme-linked immunosorbent assay for measurements of soluble HLA-G protein. PG - 206-15 LID - 10.1111/tan.12357 [doi] AB - The human leukocyte antigen (HLA) class Ib molecule, HLA-G, has gained increased attention because of its assumed important role in immune regulation. The HLA-G protein exists in several soluble isoforms. Most important are the actively secreted HLA-G5 full-length isoform generated by alternative splicing retaining intron 4 with a premature stop codon, and the cleavage of full-length membrane-bound HLA-G1 from the cell surface, so-called soluble HLA-G1 (sHLA-G1). A specific and sensitive immunoassay for measurements of soluble HLA-G is mandatory for conceivable routine testing and research projects. We report a novel method, a competitive immunoassay, for measuring HLA-G5/sHLA-G1 in biological fluids. The sHLA-G immunoassay is based upon a competitive enzyme-linked immunosorbent assay (ELISA) principle. It includes a recombinant sHLA-G1 protein in complex with beta2-microglobulin and a peptide as a standard, biotinylated recombinant sHLA-G1 as an indicator, and the MEM-G/9 anti-HLA-G monoclonal antibody (mAb) as the capture antibody. The specificity and sensitivity of the assay were evaluated. Testing with different recombinant HLA class I proteins and different anti-HLA class I mAbs showed that the sHLA-G immunoassay was highly specific. Optimal combinations of competitor sHLA-G1 and capture mAb concentrations were determined. Two versions of the assay were tested. One with a relatively wide dynamic range from 3.1 to 100.0 ng/ml, and another more sensitive version ranging from 1.6 to 12.5 ng/ml. An intra-assay coefficient of variation (CV) of 15.5% at 88 ng/ml and an inter-assay CV of 23.1% at 39 ng/ml were determined. An assay based on the competitive sHLA-G ELISA may be important for measurements of sHLA-G proteins in several conditions: assisted reproduction, organ transplantation, cancer, and certain pregnancy complications, both in research studies and possibly in the future also for clinical routine use. CI - (c) 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Rasmussen, M AU - Rasmussen M AD - Department of Clinical Biochemistry, Centre for Immune Regulation and Reproductive Immunology (CIRRI), Copenhagen University Hospital (Roskilde) and Roskilde Hospital, Roskilde, Denmark. FAU - Dahl, M AU - Dahl M FAU - Buus, S AU - Buus S FAU - Djurisic, S AU - Djurisic S FAU - Ohlsson, J AU - Ohlsson J FAU - Hviid, T V F AU - Hviid TV LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140502 PL - England TA - Tissue Antigens JT - Tissue antigens JID - 0331072 RN - 0 (Antibodies, Monoclonal) RN - 0 (Culture Media, Conditioned) RN - 0 (HLA-G Antigens) RN - 0 (Recombinant Proteins) SB - IM MH - Antibodies, Monoclonal/immunology MH - Antibody Specificity/immunology MH - Biotinylation MH - Cell Line, Tumor MH - Culture Media, Conditioned/chemistry MH - Enzyme-Linked Immunosorbent Assay/*methods MH - HLA-G Antigens/*blood/immunology MH - Humans MH - Recombinant Proteins/immunology MH - Reference Standards MH - Sensitivity and Specificity MH - Solubility OTO - NOTNLM OT - competitive enzyme-linked immunosorbent assay OT - human leukocyte antigen OT - human leukocyte antigen class Ib OT - soluble human leukocyte antigen-G EDAT- 2014/05/03 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/05/03 06:00 PHST- 2013/10/28 00:00 [received] PHST- 2014/03/24 00:00 [revised] PHST- 2014/03/25 00:00 [accepted] PHST- 2014/05/03 06:00 [entrez] PHST- 2014/05/03 06:00 [pubmed] PHST- 2015/03/31 06:00 [medline] AID - 10.1111/tan.12357 [doi] PST - ppublish SO - Tissue Antigens. 2014 Aug;84(2):206-15. doi: 10.1111/tan.12357. Epub 2014 May 2.